LIFEVANTAGE CORP Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
LIFEVANTAGE CORP (LFVN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2018-06-30, per its 10-K filed 2018-08-15.
Discontinued › Income Statement
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2018-08-15
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-12-31 was 42.00K shares, a 40.85% decline year-over-year.
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2018 was 0.00 shares.
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2016 was 66.00K shares, a 7.04% decline from fiscal 2015.
- LIFEVANTAGE CORP incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2015 was 71.00K shares, a 84.26% decline from fiscal 2014.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-06-30 | 0.00 shares 10-K · filed 2018-08-15 | |||||||
| 2017-12-31 | 0.00 shares 10-Q · filed 2018-02-07 | 0.00 shares 10-Q · filed 2018-02-07 | ||||||
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-08 | |||||||
| 2017-06-30 | 0.00 shares 10-K · filed 2018-08-15 | |||||||
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-10 | 0.00 shares 10-Q · filed 2017-05-10 | ||||||
| 2016-12-31 | 42.00K shares 10-Q · filed 2018-02-07 | 44.00K shares 10-Q · filed 2018-02-07 | ||||||
| 2016-09-30 | 45.00K shares 10-Q · filed 2017-11-08 | |||||||
| 2016-06-30 | 66.00K shares 10-K · filed 2018-08-15 | |||||||
| 2016-03-31 | 73.00K shares 10-Q · filed 2017-05-10 | 70.00K shares 10-Q · filed 2017-05-10 | ||||||
| 2015-12-31 | 71.00K shares 10-Q · filed 2017-02-08 | 67.00K shares 10-Q · filed 2017-02-08 | ||||||
| 2015-09-30 | 62.00K shares 10-Q · filed 2016-12-12 | |||||||
| 2015-06-30 | 71.00K shares 10-K · filed 2017-09-07 | 495.00K shares 10-K · filed 2015-09-01 | ||||||
| 2015-03-31 | 70.00K shares 10-Q/A · filed 2016-07-19 | 490.00K shares 10-Q · filed 2015-05-06 | 73.00K shares 10-Q/A · filed 2016-07-19 | 508.00K shares 10-Q · filed 2015-05-06 | ||||
| 2014-12-31 | 212.00K shares 10-Q · filed 2016-02-09 | 1.48M shares 10-Q · filed 2015-02-04 | 212.00K shares 10-Q · filed 2016-02-09 | 1.48M shares 10-Q · filed 2015-02-04 | ||||
| 2014-09-30 | 381.00K shares 10-Q · filed 2015-11-04 | 2.67M shares 10-Q · filed 2014-11-06 | ||||||
| 2014-06-30 | 451.00K shares 10-K · filed 2016-12-12 | 3.16M shares 10-K · filed 2014-09-10 | ||||||
| 2014-03-31 | 3.01M shares 10-Q · filed 2015-05-06 | 3.40M shares 10-Q · filed 2015-05-06 | ||||||
| 2013-12-31 | 3.69M shares 10-Q · filed 2015-02-04 | 3.80M shares 10-Q · filed 2015-02-04 | ||||||
| 2013-09-30 | 5.23M shares 10-Q · filed 2014-11-06 | |||||||
| 2013-06-30 | 6.78M shares 10-K · filed 2015-09-01 | |||||||
| 2012-06-30 | 10.12M shares 10-K · filed 2014-09-10 | 10.12M shares 10-K · filed 2012-09-10 | ||||||
| 2011-06-30 | 0.00 shares 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |